Hangzhou Changxi Pharmaceutical has entered an exclusive commercialization collaboration with Huadong Medicine for its innovative respiratory therapy, CXG87 (modified budesonide/formoterol inhalation powder), in mainland China.
CXG87: A Next-Gen Inhaled Therapy
CXG87 is a Class 2.2 novel drug independently developed by Changxi for respiratory diseases like asthma. Key advantages include:
- Lower flow rate dependence, making it easier for patients with limited inspiratory flow.
- Single-dose powder inhaler, reducing misuse and ensuring consistent therapeutic performance.
- Phase III clinical trial completed enrollment, with NDA submission expected in H1 2026.
“CXG87 is the first product developed on our unique VFC platform and highlights both its scientific and commercial value.”
- Dr. Donghao Chen, founder & CEO of Changxi Pharmaceuticals.
Strategic Partnership
Under the agreement:
- Changxi Pharmaceutical will handle R&D, registration, production, and supply.
- Huadong Medicine will lead commercial promotion in China.
“Leveraging our nationwide network and expertise, CXG87 is expected to achieve rapid market access and broad patient coverage.”
- Lv Liang, chairman of Huadong Medicine.
Clinical and Commercial Impact
CXG87 aims to benefit asthma patients with inspiratory airflow limitations, offering a more reliable alternative to existing therapies like Symbicort Turbuhaler. This collaboration ensures accelerated access to innovative respiratory care for patients across China.
About the Companies
Changxi Pharmaceuticals: A clinical-stage biotech focused on innovative dry powder inhalers (DPI), built on proprietary pulverization/mixing and spray-drying platforms.
Huadong Medicine: Founded in 1993, it operates across the entire pharmaceutical value chain, including R&D, commercial operations, medical aesthetics, and industrial microbiology, with over 30 years of industry expertise.
